NCT01404325View on ClinicalTrials.gov

Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

February 1, 2012

Primary Completion Date

January 5, 2017

Study Completion Date

January 5, 2017

Conditions
Lung Transplantation
Interventions
DRUG

standard therapy

centre specific CNI-based triple drug immunosuppression

DRUG

Everolimus

quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids

Trial Locations (9)

10117

Novartis Investigative Site, Berlin

13353

Novartis Investigative Site, Berlin

20246

Novartis Investigative Site, Hamburg

30625

Novartis Investigative Site, Hanover

45147

Novartis Investigative Site, Essen

66421

Novartis Investigative Site, Homburg

79106

Novartis Investigative Site, Freiburg im Breisgau

81377

Novartis Investigative Site, München

04103

Novartis Investigative Site, Leipzig

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY